[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-c-virus-hcv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-c-virus-hcv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,76,113,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624196","assessing-performance-of-a-hepatitis-c-emergency-department-hepc-end-screening-tool-it-integration-process-for-electronic-health-record-system-100624196",false,"NCT07406490","Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System","HepC-EnD","Inclusion Criteria:\n\n* 18-79 years of age\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* Medically unstable",true,"ALL","18 Years","79 Years",{"count":21,"type":22},6466,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to develop, implement, and evaluate a machine learning algorithm-based Hepatitis C Emergency Department (HepC-EnD) screening tool for use in emergency departments (EDs) to identify patients at high risk of hepatitis C virus (HCV) infection. HepC-EnD will be integrated into the University of Florida Health electronic health record (EHR) system as a best practice alert (BPA) pop-up for ED providers, notifying them of patients at high risk for HCV infection and recommending both HCV and human immunodeficiency virus (HIV) screening. Investigators aim to enhance the screening and diagnosis of individuals who may otherwise remain undiagnosed and untreated.\n\nThe implementation outcomes (e.g., usability) and effectiveness outcomes (e.g., HCV screening and diagnosis rates) of HepC-EnD targeted screening will be compared with universal screening (FOCUS) and conventional physician-initiated screening programs in EDs.",[26,27,28],"Hepatitis C Virus (HCV)","Hepatitis C Virus (HCV) Infection","HIV (Human Immunodeficiency Virus)",[30,31,32,33,34,35,36],"Emergency Department","Hepatitis C","Human Immunodeficiency Virus","Implementation Study","Machine Learning","Screening Algorithm","High-Risk Prediction","NOT_YET_RECRUITING","2026-04-28",{"date":40,"type":41},"2026-04-29","ACTUAL",{"date":43,"type":22},"2026-07-01",{"date":45,"type":22},"2027-07",{"name":47,"class":48},"University of Florida","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100625185","study-of-glecaprevirpibrentasvir-to-assess-safety-through-real-world-data-100625185","NCT07419347","Study of Glecaprevir\u002FPibrentasvir to Assess Safety Through Real-World Data","Retrospective Analysis of Glecaprevir\u002FPibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data","Inclusion Criteria:\n\n* Prescribed 8 weeks of Glecaprevir\u002FPibrentasvir (G\u002FP).\n* Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)\n* Is concomitantly on one or more prescription medications or illicit drugs.\n\nExclusion Criteria:\n\n* Treated with DAAs other than G\u002FP.\n* History of decompensated cirrhosis.\n* Had Hepatitis-B virus (HBV) infection.\n* Had hepatocellular carcinoma (HCC).",{"count":58,"type":22},2000,"The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir\u002FPibrentasvir (G\u002FP) in participants taking either prescribed or illicit drugs.",[26],[26,62,63],"Glecaprevir","Pibrentasvir","RECRUITING","2026-04-15",{"date":67,"type":41},"2026-04-16",{"date":69,"type":41},"2026-02-27",{"date":71,"type":22},"2026-06",{"name":73,"class":74},"AbbVie","INDUSTRY",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":83,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":97,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":49},"100626311","california-meps-hub-100626311","NCT07433985","California MEPS Hub","California Hub for HIV\u002FSTI\u002FSUD Prevention Research With Reentry Populations","Inclusion Criteria:\n\nRCT Participants\n\n* Assigned male at birth\n* Ages 18 - 59\n* Was released from incarceration in the previous 12 months (incarceration is defined as a stay in jail, prison, or detention centers for over 24 hours)\n* Reports an SUD diagnosis or seeking SUD services at any time in the 24 months prior to enrollment\n* During the 24 months prior to enrollment, either:\n\n  1. Reports intercourse with a person assigned male at birth\n  2. Reports injection drug use\n* Has not received an HIV diagnosis (based on self-report)\n* Possesses a smartphone or plans to obtain one\n* Plans to reside within designated jurisdictions (counties) for the 9 months following enrollment\n\nCBO and agency staff participating in implementation surveys or interviews\n\n* \\>=18 years of age\n* Employed at a study site or otherwise involved with intervention implementation and\u002For maintenance OR works at an agency in the counties where the study is taking place (Los Angeles, Riverside, San Bernardino, and Alameda counties, California).\n* Willing to provide informed consent for participation.\n\nExclusion Criteria:\n\nRCT Participants:\n\n* Does not have a smart phone and is not willing to obtain one\n* Is not able to speak and understand English\n* Has insufficient reading skills to operate a mobile application on a cell phone\n\nCBO participating in implementation interviews\n\n\\- n\u002Fa","MALE","59 Years",{"count":86,"type":22},318,"INTERVENTIONAL",[89],"NA","The California Hub for HIV\u002FSUD Prevention Research with Reentry Populations addresses the question: \"Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider range of clients?\"\n\nThe Mobile Enhanced Prevention Support (MEPS) intervention was originally implemented in Los Angeles County and was proven successful in promoting biomedical HIV prevention (PrEP) uptake and preventative screenings in people who used drugs who recently left incarceration. MEPS is an evidence-based intervention for people with substance use disorders (SUD) that incorporates a client-centered planning session, including trained peer mentors, service utilization incentives, and a mobile application (GeoPass).\n\nThe study includes a randomized controlled trial (RCT) across three community partners located in Riverside and Alameda Counties. At least 300 people will be enrolled in these three counties; the first 200 will be randomized to either receive the intervention or usual care, with the final 100 all receiving the intervention. The primary implementation outcome for the study involves using an implementation science framework and assessment tools to examine MEPS's implementation. Key outcomes include how well the implementation strategies used support intervention enrollment and retention, integration with existing services in each partnering community agency, and perceived intervention acceptability, feasibility, appropriateness, and maintenance at 6- and 12-months. The primary effectiveness outcome for the study is an increase in HIV testing, PrEP uptake and adherence, and SUD service utilization at 6 months and 12 months in the MEPS compared to the usual care group. Secondary effectiveness outcomes include frequency of service use for SUDs, hepatitis C virus testing, and linkage to care for those who test positive for HIV or hepatitis C.",[92,93,94,95,26,96],"HIV Prevention","Sexually Transmitted Infections (STI)","Preexposure Prophylaxis (PrEP)","Incarceration","Substance Use Disorder (SUD)",[98,99,100,101,102,103],"implementation science","contingency management","mobile health technology (mHealth)","community based participatory research","type 3 hybrid implementation effectiveness trial","randomized controlled trial","2026-04-01",{"date":106,"type":41},"2026-04-03",{"date":108,"type":41},"2025-12-01",{"date":110,"type":22},"2029-07-31",{"name":112,"class":48},"University of California, Los Angeles",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":121,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":124,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":134,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100622850","magia-h3s-point-of-care-test-performance-for-hiv-hbv-hcv-and-syphilis-screening-in-pregnant-women-in-dr-congo-100622850","NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.","FEMALE",{"count":123,"type":22},7500,"12 Months","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[127,128,26,129,130,131,132,133],"HIV - Human Immunodeficiency Virus","HBV (Hepatitis B Virus)","Syphilis","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B",[135,136,137],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","2026-01-28",{"date":140,"type":41},"2026-02-05",{"date":142,"type":22},"2026-03-01",{"date":144,"type":22},"2027-12-21",{"name":146,"class":48},"Gardiens de Vies",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":87,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100602339","enhancing-uptake-of-needle-and-syringe-programs-in-canadian-federal-prisons-100602339","NCT07122219","Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons","Inclusion Criteria:\n\n* All people incarcerated at a study site during the intervention period\n\nExclusion Criteria:\n\n\\- None (site level intervention)",{"count":154,"type":22},548,[89],"This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison. The study is being conducted in nine federal prisons, including five women's prisons, where a higher proportion of incarcerated individuals report a history of injection drug use. This study aims to improve PNEP adoption and sustainability by identifying barriers and facilitators and implementing evidence-based strategies to enhance program engagement.",[158,26],"HIV",[160,161,162,163,158,31],"Needle-Exchange Programs","Prisons","Health Services for Prisoners","Blood-Borne Pathogens","2025-12-19",{"date":166,"type":41},"2025-12-29",{"date":168,"type":41},"2024-10-01",{"date":170,"type":22},"2029-09-30",{"name":172,"class":48},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",9]